8-K filing — TENAX THERAPEUTICS, INC. (TENX)
Filed: 2026-09-09 AccNo: 0001193125-26-385910 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5
Evercore ISI Group analyst Gavin Clark-Gartner downgrades Tenax Therapeutics (NASDAQ:TENX) from Outperform to In-Line and lowers the price target from $39 to $5.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tenax Therapeutics shares are trading lower after Guggenheim downgraded the stock from Buy to Neutral rating.
This Sempra Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Mizuho analyst
Guggenheim Downgrades Tenax Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral.